Home / Leaderboard / New Enterprise Associates, Inc.
New Enterprise Associates, Inc.
Scott Sandell · Venture Capital · Venture
New Enterprise Associates (NEA) is a global venture capital firm founded in 1977 by Richard Kramlich, Chuck Newhall, and Frank Bonsal. Headquartered in Menlo Park, California, the firm is one of the world's largest venture capital organizations, managing over $25 billion in committed capital. NEA focuses primarily on the technology and healthcare sectors, investing across all stages of a company's lifecycle from seed and early-stage rounds to late-stage growth equity. Over its nearly five-decade history, the firm has supported more than 1,000 companies, achieving more than 250 IPOs and 300 acquisitions. Its portfolio includes notable names such as Salesforce, Workday, and Robinhood, reflecting its role as a key player in the global innovation economy.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +45.3% |
| YTD return | +7.9% |
| Sharpe ratio | 4.12 |
| Win rate | 30% |
| AUM | $1.6B |
| Inception | Oct 1, 2025 |
| Updated | Sep 18, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $1.6B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://www.nea.com |
Current Holdings
Updated on Sep 18, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| MBX | MBX Biosciences, Inc. Common Stock | 14.4% | +162.0% |
| TRVI | Trevi Therapeutics Inc | 14.0% | +35.6% |
| SGP | SpyGlass Pharma, Inc. | 12.1% | +23.3% |
| CELC | Celcuity LLC | 9.5% | +2.8% |
| SVRA | Savara Inc | 8.1% | +32.4% |
| ZBIO | Zenas BioPharma, Inc. Common Stock | 8.0% | +52.3% |
| GLUE | Monte Rosa Therapeutics Inc | 5.7% | +18.0% |
| COUR | Coursera Inc | 5.3% | -32.6% |
| TUYA | Tuya Inc ADR | 4.7% | -28.7% |
| AUPH | Aurinia Pharmaceuticals Inc | 4.0% | +31.3% |
| CRSP | Crispr Therapeutics AG | 3.8% | -4.8% |
| ORIC | Oric Pharmaceuticals Inc | 3.4% | +20.6% |
| IVA | Inventiva Sa | 1.9% | -37.1% |
| PHAT | Phathom Pharmaceuticals Inc | 1.1% | -36.7% |
| KRRO | Frequency Therapeutics Inc | 1.1% | -11.6% |
| XFOR | X4 Pharmaceuticals Inc | 0.8% | -4.6% |
| BDTX | Black Diamond Therapeutics Inc | 0.6% | -21.4% |
| NKTX | Nkarta Inc | 0.6% | -6.2% |
| CSBR | Champions Oncology Inc | 0.5% | -13.3% |
| CVRX | CVRx Inc | 0.4% | -56.4% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Aug 31, 2026 | SELL | SVRA | 8.4% → 8.1% |
| Aug 31, 2026 | BUY | NKTX | 0.5% → 0.6% |
| Aug 31, 2026 | SELL | ZBIO | 8.0% → 8.0% |
| Aug 31, 2026 | BUY | MBX | 15.0% → 14.4% |
| Aug 31, 2026 | BUY | CSBR | 0.6% → 0.5% |
Investment Style Analysis
New Enterprise Associates, Inc. is widely recognized for employing a Venture strategy. As of Sep 18, 2026, the firm oversees approximately $1.6B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology and Other sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Aug 31, New Enterprise Associates, Inc. made a significant move by reducing the position in SVRA. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
NEA’s investment philosophy is centered on forming enduring, long-term partnerships with visionary entrepreneurs to build category-defining companies. The firm employs a "founder-first" approach, viewing each investment not just as a financial transaction but as a commitment to supporting people throughout their entire entrepreneurial journey. By leveraging deep domain expertise in healthcare and technology, NEA provides hands-on guidance and a robust platform of resources to help companies scale from initial concept to public offering. Their strategy is characterized by a diversified mandate that allows for high-conviction investing in disruptive innovations, aiming to solve complex problems and create meaningful global impact across various macroeconomic environments.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with New Enterprise Associates, Inc..
Similar Investment Style
Based on Venture.
- Accel Partners — Jim Swartz · 3M +18.1%
- Deer Management Co. LLC — Robert P. Goodman · 3M -8.6%
- Nextech Invest Ltd. — Alfred Scheidegger · 3M +9.7%
- Sofinnova Investment, Inc. — James Healy · 3M +10.4%
Frequently asked questions
How is the simulated portfolio for New Enterprise Associates, Inc. constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is New Enterprise Associates, Inc.'s largest holding?
As of the latest filing, New Enterprise Associates, Inc.'s top position is MBX Biosciences, Inc. Common Stock (MBX), representing 14.4% of the portfolio. This reflects a high-conviction bet by the institution.
What is New Enterprise Associates, Inc.'s historical performance and risk profile?
Our simulation indicates a total return of +45.3% with a win rate of 30%. Notably, the portfolio maintains a Sharpe Ratio of 4.12, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does New Enterprise Associates, Inc. primarily invest in?
New Enterprise Associates, Inc. has a strong preference for the Biotechnology sector, which makes up 77.6% of their disclosed assets. The portfolio also has exposure to Other, indicating a specific thematic focus.
Is New Enterprise Associates, Inc.'s portfolio concentrated or diversified?
New Enterprise Associates, Inc. runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 40.4% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has New Enterprise Associates, Inc. performed in 2026?
Our AI-simulated model portfolio for New Enterprise Associates, Inc. tracks a Year-to-Date (YTD) return of +7.9%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Scott Sandell manage New Enterprise Associates, Inc. directly?
Yes, Scott Sandell serves as the key portfolio manager for New Enterprise Associates, Inc., overseeing the investment strategy and final capital allocation decisions.